Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Razvan Cristescu

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
Immunity|January 5, 2022
Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor typesAparna Chhibber, Lingkang Huang, Hong Zhang, et al.
Journal for Immunotherapy of Cancer|February 1, 2022
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumorsRazvan Cristescu, Deepti Aurora-Garg, Andrew Albright, et al.
Gynecologic Oncology|June 25, 2026
Technical evaluation of commercially available homologous recombination deficiency assays using MyChoice CDx as reference in ovarian cancerAlexander Yarunin, Ping Qiu, Xiaodun Li, et al.
Journal for Immunotherapy of Cancer|July 6, 2022
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational studyIrene M Shui, Xiao Qiao Liu, Qing Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2018
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II TrialJinhyun Cho, Hae Su Kim, Bo Mi Ku, et al.
Oncoimmunology|September 18, 2018
Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancerSong Ee Park, Kyunghee Park, Eunjin Lee, et al.
Journal of Cellular and Molecular Medicine|August 27, 2019
Identification of predictive genetic signatures of Cytarabine responsiveness using a 3D acute myeloid leukaemia modelHaiyan Xu, Eric S Muise, Sarah Javaid, et al.
JCO Precision Oncology|March 21, 2025
Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 StudiesYelena Y Janjigian, Michael Cecchini, Kohei Shitara, et al.
Nature Communications|January 9, 2016
Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccinationSlim Fourati, Razvan Cristescu, Andrey Loboda, et al.
Molecular Cancer Therapeutics|March 18, 2016
An Unbiased Oncology Compound Screen to Identify Novel Combination StrategiesJennifer O'Neil, Yair Benita, Igor Feldman, et al.
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Immunity|January 5, 2022
Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor typesAparna Chhibber, Lingkang Huang, Hong Zhang, et al.
Journal for Immunotherapy of Cancer|February 1, 2022
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumorsRazvan Cristescu, Deepti Aurora-Garg, Andrew Albright, et al.
Gynecologic Oncology|June 25, 2026
Technical evaluation of commercially available homologous recombination deficiency assays using MyChoice CDx as reference in ovarian cancerAlexander Yarunin, Ping Qiu, Xiaodun Li, et al.
Journal for Immunotherapy of Cancer|July 6, 2022
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational studyIrene M Shui, Xiao Qiao Liu, Qing Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2018
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II TrialJinhyun Cho, Hae Su Kim, Bo Mi Ku, et al.
Oncoimmunology|September 18, 2018
Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancerSong Ee Park, Kyunghee Park, Eunjin Lee, et al.
Journal of Cellular and Molecular Medicine|August 27, 2019
Identification of predictive genetic signatures of Cytarabine responsiveness using a 3D acute myeloid leukaemia modelHaiyan Xu, Eric S Muise, Sarah Javaid, et al.
JCO Precision Oncology|March 21, 2025
Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 StudiesYelena Y Janjigian, Michael Cecchini, Kohei Shitara, et al.
Nature Communications|January 9, 2016
Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccinationSlim Fourati, Razvan Cristescu, Andrey Loboda, et al.
Molecular Cancer Therapeutics|March 18, 2016
An Unbiased Oncology Compound Screen to Identify Novel Combination StrategiesJennifer O'Neil, Yair Benita, Igor Feldman, et al.
Pageof 6